Other News To Note

NPS Pharmaceuticals Inc., of Bedminster, N.J., partnered with GlaxoSmithKline plc, of London, to develop two calcilytic compounds currently belonging to GSK. The compounds have relevance for rare disorders of calcium receptor activity, including hypocalcemia with hypercalciuria.